Warning Letter — Northland Nuclear Medicine, LLC
The FDA issued a Warning Letter to Northland Nuclear Medicine, LLC following an inspection by the Center for Drug Evaluation and Research (CDER). The specific regulatory violations are not detailed in the provided excerpt but led to formal enforcement action.
This action affects Northland Nuclear Medicine, LLC, as well as regulatory and quality assurance personnel involved in nuclear medicine and radiopharmaceutical compounding.
The issuance of a Warning Letter by CDER indicates that the firm's initial response to inspectional observations was likely insufficient to address underlying compliance concerns. This suggests a heightened level of regulatory scrutiny for radiopharmaceutical providers regarding adherence to federal standards.
Quality teams should review current CGMP compliance for radiopharmaceutical compounding and preparation. Regulatory departments must ensure that responses to inspectional findings address the root causes of observations to prevent formal enforcement actions.
FDA Warning Letter issued to: Northland Nuclear Medicine, LLC. 10/22/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/northland-nuclear-medicine-llc-736893-10222026
Open in openFDA / FDA.gov